Compare Citius Pharmaceuticals Inc (CTXR) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Oscar Health Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Oscar Health Inc trades at $33.37 (market cap $10.22B). The key difference: Oscar Health Inc is far larger — about 750.4× Citius Pharmaceuticals Inc's market cap, and Oscar Health Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Oscar Health Inc for 15 Days on average.
| CTXR | OSCR | |
|---|---|---|
Market Cap | $13.62M | $10.22B |
Volume | 132,438 | 4,123,394 |
Sector | Health | Health |
52-Week High | $1.82 | $33.81 |
52-Week Low | $0.48 | $10.85 |
Typical Hold Time | 17 Days | 15 Days |
Enterprise Value | $3.79M | $6.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
OSCR trades at $33.1, up 0.58% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 and Q2 2026 earnings beats, with revenue growth from $11.7B in 2025 to a projected $15.3B in 2026, turning to a net profit. Analyst consensus is a $34 price target, with 31% buy ratings. Recent news highlights market share gains and raised 2026 guidance following its Investor Day.
The outlook is positive, driven by execution in the ACA market and new growth avenues, but risks include rising medical costs threatening profitability and a high P/E ratio. The stock offers growth potential if margin expansion continues as guided.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
